Humana Cancer Proteomics: From Bench to Bedside (Cancer Drug Discovery and Development)

Product Description This book covers current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics. Review From the reviews: "This is a comprehensive overview of the current state of knowledge in the area of cancer proteomics … . appropriate for cancer researchers of diverse specialties and clinicians conducting basic or clinical cancer research. … a book that provides a truly comprehensive look at the utility of proteomics from ‘bench to bedside.’ All chapters are well referenced and of appropriate length, and many contain helpful illustrations. … an excellent book that is appropriate for scientists and clinicians with an interest in cancer proteomics." (John D. Robertson, Doody’s Review Service, May, 2008) "This book … provides the reader with a current perspective and anticipated uses of proteomic strategies in cancer therapy as well as basic cancer research. … the book provides a broad account of the area of cancer proteomics and adequately covers issues relevant to the use of proteomic strategies in clinical research. … The book would be of interest to clinicians and basic cancer researchers … who are already involved in, or who are considering the use of proteomics in their work." (JF Timms, British Journal of Cancer, Vol. 99 (4), 2008) From the Back Cover Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice.